Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

14549 items
10:36 AM, Sep 13, 2018  |  BC Innovations | Translation in Brief

Keeping CRISPR on target

Editas Medicine Inc. (NASDAQ:EDIT) has developed an in silico model of Staphylococcus aureus Cas9 (SaCas9) gene editing to help it select guide RNA sequences with minimal risk of off-target effects. Editas’ lead candidate EDIT-101 is built...
12:37 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a tool...
12:36 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture studies identified a pteridinylbenzamide-based dual PLK1/BRD4 inhibitor that could help treat AML. Chemical synthesis and screening of analogs of a pteridinylbenzamide-based tool compound PLK1 inhibitor in enzyme activity assays...
12:35 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting HspD1 could help treat glioblastoma multiforme (GBM). In glioma and GBM patients, high tumor levels of HspD1 correlated with poor survival. In a...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease

Indication: Rheumatoid arthritis (RA) In vitro and mouse studies suggest neutrophil plasma membrane-based nanoparticles could help treat RA. The nanoparticles consist of a poly(lactic-co-glycolic acid) (PLGA) core coated with activated primary human peripheral blood neutrophil-derived plasma...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest inhibiting NFKB2 in combination with radiotherapy could help treat cancer. In glioblastoma patients treated with radiotherapy, high postmortem levels of NFKB2 mRNA in brain tissue...
12:34 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat contact hypersensitivity. The fusion consists of a 28-amino acid, cell-penetrating peptide from the N-terminus of Drosophila antennapedia (Antp) and...
12:32 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated STAT1...
12:32 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Mouse studies suggest inhibiting ZMPSTE24 with Kaletra lopinavir/ritonavir could help treat acute lung injury (ALI). In a mouse model of ventilator-induced ALI, systemic ZMPSTE24 knockout decreased markers of injury and increased oxygenation...
12:32 PM, Sep 10, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/metabolic

INDICATION: Metabolic Mouse studies suggest ASL gene therapy could help treat argininosuccinic aciduria, which is caused by ASL mutations. In a mouse model of the disease, an adeno-associated viral (AAV) serotype 8 (AAV8) vector encoding ASL...

Pages